[go: up one dir, main page]

AR059071A1 - Metodos y composicionesque comprenden dextrano con peso molecular de 1 a 100 kda - Google Patents

Metodos y composicionesque comprenden dextrano con peso molecular de 1 a 100 kda

Info

Publication number
AR059071A1
AR059071A1 ARP070100220A ARP070100220A AR059071A1 AR 059071 A1 AR059071 A1 AR 059071A1 AR P070100220 A ARP070100220 A AR P070100220A AR P070100220 A ARP070100220 A AR P070100220A AR 059071 A1 AR059071 A1 AR 059071A1
Authority
AR
Argentina
Prior art keywords
kda
molecular weight
liquid composition
compositions
methods
Prior art date
Application number
ARP070100220A
Other languages
English (en)
Original Assignee
Bows Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37930329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059071(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bows Pharmaceuticals Ag filed Critical Bows Pharmaceuticals Ag
Publication of AR059071A1 publication Critical patent/AR059071A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un implante solido o semisolido que se obtiene al proveer una composicion líquida que comprende una solucion acuosa de dextrano con peso molecular de 1,0-100 kDa e introducir la composicion líquida en el cuerpo de un mamífero, por lo que se forma el implante in situ en el cuerpo del mamífero. Un proceso para preparar una composicion de utilidad para la aplicacion biomédica, que comprende las etapas de proveer una composicion líquida que comprende una solucion acuosa de dextrano con un peso molecular de 1-100 kDa; y llevar la composicion líquida a solidificacion; por lo que se elimina gradualmente el agua de la composicion líquida durante la solidificacion. Un artículo biomédico preparado a partir de la composicion.
ARP070100220A 2006-01-18 2007-01-18 Metodos y composicionesque comprenden dextrano con peso molecular de 1 a 100 kda AR059071A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0600091A SE529040C2 (sv) 2006-01-18 2006-01-18 Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin

Publications (1)

Publication Number Publication Date
AR059071A1 true AR059071A1 (es) 2008-03-12

Family

ID=37930329

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100220A AR059071A1 (es) 2006-01-18 2007-01-18 Metodos y composicionesque comprenden dextrano con peso molecular de 1 a 100 kda

Country Status (16)

Country Link
US (3) US20080305139A1 (es)
EP (2) EP1973570B1 (es)
JP (1) JP2009523791A (es)
CN (1) CN101370523A (es)
AR (1) AR059071A1 (es)
AT (1) ATE448798T1 (es)
AU (1) AU2007206087A1 (es)
BR (1) BRPI0706543A2 (es)
CA (1) CA2636173A1 (es)
DE (1) DE602007003315D1 (es)
ES (1) ES2336380T3 (es)
MX (1) MX2008008924A (es)
RU (1) RU2008133635A (es)
SE (1) SE529040C2 (es)
TW (1) TW200738279A (es)
WO (1) WO2007084068A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004216908A1 (en) * 2003-03-04 2004-09-16 The Technology Development Company Ltd. Oral insulin composition and methods of making and using thereof
US9023376B2 (en) * 2008-06-27 2015-05-05 The University Of Akron Nanofiber-reinforced composition for application to surgical wounds
KR101003331B1 (ko) 2010-05-11 2010-12-23 조강선 피부 충전제 조성물
WO2015123779A1 (en) * 2014-02-20 2015-08-27 Polyvalor, Limited Partnership Lyophilized polymer scaffold compositions, processes for preparation and use in anabolic wound repair
US10426796B2 (en) * 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204244L (sv) 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
DE3500268A1 (de) * 1985-01-05 1986-07-10 Hoechst Ag, 6230 Frankfurt Praeparate mit verzoegerter wirkung, verfahren zu deren herstellung sowie entsprechende mittel zur human- bzw. veterinaermedizinischen anwendung
EP0247077A1 (en) 1985-10-22 1987-12-02 ROBINSON, Eric Process for cell immobilisation
JPS62152816A (ja) * 1985-12-27 1987-07-07 Sumitomo Pharmaceut Co Ltd ゲル状高分子の成形方法
JPH0720483B2 (ja) * 1987-05-29 1995-03-08 住友製薬株式会社 高粘度糊状組成物成形体の乾燥法
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
PT1117386E (pt) 1998-09-28 2005-04-29 Warner Lambert Co Administracao enterica e colonica utilizando capsulas de hpmc
EP1074248A1 (en) 1999-07-08 2001-02-07 Arnold Hilgers Delivery system for biological material
US20030026844A1 (en) 2000-04-18 2003-02-06 Hee-Yong Lee Injectable sustained release pharmaceutical composition and processes for preparing the same
EP1184032A1 (en) 2000-08-31 2002-03-06 OctoPlus B.V. Dextran hydrogels
CA2460867C (en) 2001-09-19 2011-04-12 Elan Pharma International Ltd. Nanoparticulate insulin formulations
AU2004216908A1 (en) * 2003-03-04 2004-09-16 The Technology Development Company Ltd. Oral insulin composition and methods of making and using thereof
TW200603843A (en) * 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method

Also Published As

Publication number Publication date
ATE448798T1 (de) 2009-12-15
US20090281020A1 (en) 2009-11-12
EP2153850A1 (en) 2010-02-17
MX2008008924A (es) 2008-09-05
EP1973570B1 (en) 2009-11-18
AU2007206087A1 (en) 2007-07-26
DE602007003315D1 (de) 2009-12-31
EP1973570A1 (en) 2008-10-01
US20100172950A1 (en) 2010-07-08
TW200738279A (en) 2007-10-16
BRPI0706543A2 (pt) 2011-03-29
CN101370523A (zh) 2009-02-18
ES2336380T3 (es) 2010-04-12
SE0600091L (sv) 2007-04-17
RU2008133635A (ru) 2010-02-27
US7781400B2 (en) 2010-08-24
CA2636173A1 (en) 2007-07-26
HK1125041A1 (en) 2009-07-31
JP2009523791A (ja) 2009-06-25
US20080305139A1 (en) 2008-12-11
SE529040C2 (sv) 2007-04-17
WO2007084068A1 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
AR059071A1 (es) Metodos y composicionesque comprenden dextrano con peso molecular de 1 a 100 kda
WO2008041246A3 (en) Injectable depot composition and its' process of preparation
EA200971116A1 (ru) Способ желатинизации фиброина шелка с применением обработки ультразвуком
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
ATE420116T1 (de) Verfahren zur herstellung von cellulosesulfat mit verbesserten eigenschaften
UY28067A1 (es) Formulaciones de deposito de liberacion controlada
AR092039A1 (es) Caucho natural que contiene nanocarbono
WO2010123945A3 (en) Silk fibroin hydrogels and uses thereof
WO2009032773A3 (en) Compositions and methods for treating demodex infestations
MX339205B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
CL2012000724A1 (es) Particula antimicrobiana bipolar en que su precursor es una particula de arcilla asimetrica y fijada con un grupo antimicrobiano al cation de coordinacion; composiciones para lavado, lavado personal, desodorante y de higiene dental que la comprenden; proceso para preparar esta particula; y uso de dicha particula.
ATE482961T1 (de) Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
MY149505A (en) Hyaluronic acid binary mixtures and therapeutic use thereof
JP2009178558A5 (es)
MX2009009006A (es) Agonistas ppar-gamma para la induccion de expresion de peptido antimicrobiano cationico en la forma de estimulantes inmunoprotectores.
WO2010007502A3 (en) Platelet fraction deriving from placental blood
TW201129396A (en) Topical formulation
BR112015029615A8 (pt) uso cosmético, processo cosmético, composição e uso de um material silicioso
EP2328550A4 (en) MUCOADHERENT COMPOSITIONS AND THEIR USE
AR072921A1 (es) Mejoras relacionadas con composiciones que contienen agentes tensioactivos
BR112012015449A2 (pt) suspensão de monoidrato de calcipotriol, monoidrato de calcipotriol, processo para preparar nanocristais de monoidrato de calcipotriol, e, composição farmacêutica
CL2008002079A1 (es) Dispositivo para utilizar a temperaturas sobre 1000 grados celsius o en aceros fundidos,donde el dispositivo tiene un cuerpo basado en arena y/o bolas o fibras ahuecadas resistentes a altas temperaturas, el en cuerpo contiene water glass ( solucion viscosa de silicato de sodio en agua) y cemneto; uso del dispositivo y metodo para su produccion.
MX343704B (es) Formulaciones de lavado liquidas a base de jabon con deposicion mejorada.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal